ViiV Healthcare

Gilead Sciences’ lenacapavir is already expected to have a significant advantage among injected HIV drugs thanks to its twice-yearly injection schedule when the company launches it for pre-exposure pr

Gilead Sciences saw stronger-than-expected growth in its HIV business in 2024 as the company looks ahead to the launch of lenacapavir, its twice-yearly injectable drug for pre-exposure prophylaxis (Pr

On the same day the Biden administration proposed a rule requiring health insurers to cover over-the-counter birth control , it released a less-heralded, but still significant, guidance requiring ins

The latest data from the Phase II study of the weekly oral combination of Gilead Sciences Inc.’s lenacapavir and Merck & Co., Inc.’s islatravir in patients living with HIV shows that efficacy is h